Barry Taylor

Barry Taylor, PhD is an Assistant Professor in the Department of Epidemiology & Biostatistics at the University of California, San Francisco (UCSF) School of Medicine. His research focuses on understanding the genetic and molecular mechanisms underlying cancer progression, particularly in oncogene-driven cancers such as melanoma and lung cancer. Key areas of interest include the impact of mutant oncogene zygosity, therapeutic resistance mechanisms, and the role of germline variants in cancer pathogenesis.

• Principal Investigator on multiple NIH grants (R01CA245069, R01CA204749, R01CA207244) studying driver mutations and targeted therapies.
• Published over 100 articles in high-impact journals like Nature, Nature Genetics, and Cancer Cell.

Research highlights include defining BRCA2 reversion mutations under therapy, identifying lineage-specific oncogenic mechanisms, and uncovering evolutionary drivers of drug resistance. His work bridges genomics, epidemiology, and clinical oncology to advance precision medicine strategies.

Grants and collaborations emphasize translational research, with studies on genomic instability, tumor evolution, and targeted drug development. Active in collaborative networks such as the PCF/SU2C International Prostate Cancer Dream Team.